SELECT

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Paziente / Popolazione Intervento / Esposizione Confronto Esito

In 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.

17.604

Disegno

Double-blind RCT

Esito

CV death, MI or stroke

Rilevanza

Risultato6.5 % vs 8.0 % (HR 0.80); mean weight loss 9.4 %.

Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232. 10.1056/NEJMoa2307563

Discussione e critica

First trial to show cardiovascular risk reduction from treating obesity itself, without diabetes. How much of the benefit is weight loss versus direct drug effect is unresolved.